MOTIVATION: Genome-wide association studies can reveal important genotype-phenotype associations; however, data quality and interpretability issues must be addressed. For drug discovery scientists seeking to prioritize targets based on the available evidence, these issues go beyond the single study. RESULTS: Here, we describe rational ranking, filtering and interpretation of inferred gene-trait associations and data aggregation across studies by leveraging existing curation and harmonization efforts. Each gene-trait association is evaluated for confidence, with scores derived solely from aggregated statistics, linking a protein-coding gene and phenotype. We propose a method for assessing confidence in gene-trait associations from evidence aggregated across studies, including a bibliometric assessment of scientific consensus based on the iCite relative citation ratio, and meanRank scores, to aggregate multivariate evidence.This method, intended for drug target hypothesis generation, scoring and ranking, has been implemented as an analytical pipeline, available as open source, with public datasets of results, and a web application designed for usability by drug discovery scientists. AVAILABILITY AND IMPLEMENTATION: Web application, datasets and source code via https://unmtid-shinyapps.net/tiga/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in December 2019 in Wuhan, China. It was quickly established that both the symptoms and the disease severity may vary from one case to another and several strains of SARS-CoV-2 have been identified. To gain a better understanding of the wide variety of SARS-CoV-2 strains and their associated symptoms, thousands of SARS-CoV-2 genomes have been sequenced in dozens of countries. In this article, we introduce COVIDomic, a multi-omics online platform designed to facilitate the analysis and interpretation of the large amount of health data collected from patients with COVID-19. The COVIDomic platform provides a comprehensive set of bioinformatic tools for the multi-modal metatranscriptomic data analysis of COVID-19 patients to determine the origin of the coronavirus strain and the expected severity of the disease. An integrative analytical workflow, which includes microbial pathogens community analysis, COVID-19 genetic epidemiology and patient stratification, allows to analyze the presence of the most common microbial organisms, their antibiotic resistance, the severity of the infection and the set of the most probable geographical locations from which the studied strain could have originated. The online platform integrates a user friendly interface which allows easy visualization of the results. We envision this tool will not only have immediate implications for management of the ongoing COVID-19 pandemic, but will also improve our readiness to respond to other infectious outbreaks.

In a drug development process, appropriate drug-binding selectivity is critical for a success drug. However the selectivity in a data source, showing the intensity of efforts, may be limited to prior knowledge of the expertise or be biased towards the hypothesis testing. With the increasing of drug screening data, it is challenging to coordinate the efforts and execute data governance at a large scale. Visual selectivity analysis for examining target selection is in demand. We proposed a knowledge-driven approach and designed an ontology reference model to provide an intuitive view of the selectivity in a drug-target interaction network data. We employed the model to carry out the visual selectivity analysis on the NIMH Psychoactive Drug Screening Program (PDSP) data and the LINCS Compounds-interacting ChEMBL Database. The analysis indicates the possible `dark matter' drug targets. The approach can be expanded to coordinate other experimental screening data and set a stage for the analysis of the mechanism of action of biological therapies.

With the increasing number of ontologies being designed to represent and manage knowledge in all sorts of sectors, ontology alignment and integration become more and more important in aggregating intelligent efforts on homogenous and heterogeneous data. From the computational perspective, it is challenging due to the ubiquitous existence of diverse classifications of same data. In this paper, we propose an active ontology integration and alignment system, which plugs in expandable learning reference context pool. In the reference context pool, we have integrated WordNet, MeSH, and external curated mapping sources (ICD9 to SNOMEDCT) with an extension to injecting UMLS. The active ontology integration and alignment system takes account of not only subsumption tree but also directed acyclic graph underlying ontologies. It allows 1) finding exact one-to-one matching terms of pairwise ontologies, 2) finding inexact one-to-one term mappings, where two terms have at least a concept in common on basis of the lexical context, and 3) finding one-to-many concept mappings, where one concept can be lexically mapped to the combination of multiple exclusive concepts.

MOTIVATION: The increasing amount of peer-reviewed manuscripts requires the development of specific mining tools to facilitate the visual exploration of evidence linking diseases and proteins. RESULTS: We developed TIN-X, the Target Importance and Novelty eXplorer, to visualize the association between proteins and diseases, based on text mining data processed from scientific literature. In the current implementation, TIN-X supports exploration of data for G-protein coupled receptors, kinases, ion channels, and nuclear receptors. TIN-X supports browsing and navigating across proteins and diseases based on ontology classes, and displays a scatter plot with two proposed new bibliometric statistics: Importance and Novelty. AVAILABILITY AND IMPLEMENTATION: http://www.newdrugtargets.org. CONTACT: [email protected].

Therapeutic intent, the reason behind the choice of a therapy and the context in which a given approach should be used, is an important aspect of medical practice. There are unmet needs with respect to current electronic mapping of drug indications. For example, the active ingredient sildenafil has 2 distinct indications, which differ solely on dosage strength. In progressing toward a practice of precision medicine, there is a need to capture and structure therapeutic intent for computational reuse, thus enabling more sophisticated decision-support tools and a possible mechanism for computer-aided drug repurposing. The indications for drugs, such as those expressed in the Structured Product Labels approved by the US Food and Drug Administration, appears to be a tractable area for developing an application ontology of therapeutic intent.

SUMMARY: The increasing availability of experimentally determined binding affinities for drugs on multiple protein targets requires the design of specific mining and visualization tools that graphically integrate chemical and biological data in an efficient environment. With this aim, we developed iPHACE, an integrative web-based tool to navigate in the pharmacological space defined by small molecule drugs contained in the IUPHAR-DB, with additional interactions present in PDSP. Extending beyond traditional querying and filtering tools, iPHACE offers a means to extract knowledge from the target profile of drugs as well as from the drug profile of protein targets. AVAILABILITY: iPHACE is available at http://cgl.imim.es/iphace/ (EU site) and http://agave.health.unm.edu/iphace/ (US mirror).